Vascular endothelial growth factor B inhibits insulin secretion in MIN6 cells and reduces Ca2+ and cyclic adenosine monophosphate levels through PI3K/AKT pathway

Figure 3 Exogenous vascular endothelial growth factor B inhibits the expression of PI3K-AKT pathway proteins in MIN6 cells, and knockdown of vascular endothelial growth factor B promotes the expression of these pathway proteins. A-C: Western blot analysis revealing the relative protein expression of phosphatidylinositol 3-kinase (PI3K)-P85 and PI3K-P110γ in cells treated with exogenous vascular endothelial growth factor B (VEGF-B, VB) and corresponding statistical data. ^aP < 0.05 vs VB-0, ^bP < 0.01 vs VB-0; D and E: Western blot analysis indicating the relative protein expression of phosphorylated (p)-serine/threonine kinase (AKT) and AKT in cells treated with exogenous VEGF-B and corresponding statistical data. ^aP < 0.05 vs VB-0 about p-AKT; F: The effect of exogenous VEGF-B protein stimulation on AKT phosphorylation. ^aP < 0.05 vs VB-0; G-I: Western blot analysis revealing the relative protein expression of PI3K-P85 and PI3K-P110γ in cells transfected with VEGF-B small interfering RNA (siRNA) and corresponding statistical data. ^aP < 0.05 vs Control, ^bP < 0.01 vs Control; J and K: Western blot analysis indicating the relative protein expression of p-AKT and AKT in cells transfected with VEGF-B siRNA and corresponding statistical data. ^aP < 0.05 vs Control, ^bP < 0.01 vs Control for p-AKT levels; ^cP < 0.01 vs Control, ^dP < 0.001 vs Control for AKT levels; L: Effect of VEGF-B knockdown on AKT phosphorylation. ^bP < 0.01 vs Con vs Control. Student's t-test was performed. PI3K: Phosphatidylinositol 3-kinase; AKT: Serine/threonine kinase; p-AKT: Phosphorylated-serine/threonine kinase; VB: Vascular endothelial growth factor B; Con: Control; Si: Small interfering RNA; MIN6: MIN6 cell.